




FIG. 1

FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 4A






FIG. 4B





7/17

FIG. 5B






FIG. 6A



9/17

FIG. 6B



10/17

FIG. 7A





FIG. 7B



12/17

FIG. 8A







FIG. 8B



CT26 Peripheral Blood






FIG. 11

FIG. 11A
Negative control
(parental 293)




FIG. 11B
293-PD-L1 low




FIG. 11E
Placenta



Positive tissue control

293-PD-L1 med




FIG. 11C

293 PD-L1 high




FIG. 11D

Tonsil





FIG. 11F

FIG. 12A




Triple-Negative Breast Cancer

FIG. 12B



Malignant Melanoma

FIG. 12C



NSCLC, adenocarcinoma